13F Holdings
中文EN

STVN Stevanato Group S.p.A. IFRS Annual reports only

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1849853 · Reporting currency EUR

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY7.4%
TTM net income YoY18.7%
TTM EPS YoY18.6%
Revenue 3-yr CAGR6.4%
Net income 3-yr CAGR-0.7%

Margins

Gross margin29.0%
Operating margin16.8%
Net margin11.8%
FCF margin1.9%
EBITDA margin—

Returns

ROE9.7%
ROA5.7%
ROIC (approx.)11.0%
Asset turnover0.49x

Leverage & solvency

Liabilities / assets41.6%
Debt / equity0.00x
Current ratio1.76x
Interest coverage35.37x

Cash quality & payout

Operating cash flow / net income2.05x
Accruals ratio-6.0%
Payout ratio10.5%
Capex / revenue22.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue1.19B1.10B1.09B983.68M843.92M
Cost of revenue842.41M801.72M745.46M663.88M578.51M
Gross profit343.88M302.32M339.89M319.80M265.40M
R&D expense25.44M31.67M35.67M34.39M29.62M
SG&A expense99.66M93.75M88.95M85.75M62.50M
Operating income198.80M161.14M200.72M192.43M162.22M
Interest expense5.62M6.11M3.73M3.36M4.29M
Pretax income189.11M160.29M189.55M187.64M165.67M
Income tax49.27M42.52M43.86M44.62M31.40M
Net income139.84M117.78M145.63M142.85M134.32M
EBITDA——279.20M257.25M218.61M
EPS (basic)0.510.430.550.540.53
EPS (diluted)0.510.430.550.540.53
Weighted avg. shares (diluted)272.96M271.15M264.98M264.70M252.69M
Balance sheet
Cash & equivalents130.60M98.27M69.60M228.74M411.04M
Receivables302.69M295.95M301.77M212.73M165.26M
Inventory268.25M245.22M255.32M213.25M148.92M
Current assets943.35M880.12M861.89M845.77M865.97M
PP&E, netmay include right-of-use assets (IFRS)1.39B1.25B1.03B641.40M392.72M
Goodwill49.98M49.98M49.98M47.24M47.24M
Intangibles36.87M33.59M30.98M32.16M31.93M
Total assets2.54B2.33B2.07B1.66B1.42B
Current liabilities535.88M477.47M574.39M462.50M338.62M
Total liabilities1.06B924.43M938.93M663.79M577.18M
Shareholders' equity1.49B1.40B1.13B996.13M842.07M
Cash flow statement
Operating cash flow286.08M155.78M105.21M103.31M133.34M
Capital expenditure263.76M302.60M433.23M235.03M107.69M
Free cash flow22.32M-146.82M-328.02M-131.72M25.64M
Investing cash flow-272.92M-310.21M-421.22M-242.95M-96.43M
Financing cash flow22.06M183.22M158.03M-44.54M254.85M
Depreciation & amortization——78.48M64.82M56.38M
Stock-based compensation——1.43M——
Dividends paid14.74M14.46M14.29M13.50M11.20M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.